Technology search

show all patents

Technology search by keyword

Results 1 - 7 of 7

Niehrs, Lee, Sun

Treatment of acute myeloid leukemia (AML) (P-1502)

Keywords: Diagnostics, Research Tools

Acute myeloid leukemia (AML) is a malignancy of the hematopoietic system and arises from uncontrolled proliferation and impaired differentiation of myeloid precursors. Current therapeutic approaches have shown limited success rates, stressing the urgency to identify genes as potential new AML biomarkers or for direct AML therapy. Novel WNT-independent functions of R-spondins (RSPOs) in inhibition of bone morphogenetic protein (BMP) signaling were investigated, identifying the role of RSPO2 in growth and differentiation of AML cells. High RSPO2 expression was also identified to associated with poor prognosis, highlighting its potential for identification of AML risk patients. The present invention relates to an inhibitor of R-spondin 2 mediated BMP receptor inhibition for use in treating and/or preventing AML more...

Brenner, Schrotz-King, Bhardwaj

Early stage colorectal cancer (CRC) diagnostic (P-1455)

Keywords: Diagnostics

Sigmoidoscopy and colonoscopy, the current gold standards for detection of CRC are limited by several disadvantages, such as high costs, limited resources and poor compliance. Therefore, other cost-effective and sensitive methods are urgently needed for the early detection of colorectal cancer. The need of an efficient and cheap test is very important from the health economic standpoint. Using blood samples this invention offers a set of proteins that can be used as a diagnostic tool for accurate diagnosis, and/or monitoring of therapy in colorectal cancer (CRC). The panel has the sensitivity of 83% for detecting early stage CRC at specificity 80% and the AUC of 0.86. For detecting all-stage CRC an AUC of s 0.82 is observed. more...

Turchinovich, Burwinkel

A method to prevent incorporation of DNA molecules into DNA libraries for massive parallel sequencing of RNA: DNA lock off (DLoff) (P-1357)

Keywords: Diagnostics, Research Tools

A method to prevent incorporation of DNA molecules into DNA libraries for massive parallel sequencing of RNA.

Brenner, Zhang

Mortality prediction through DNA methylation biomarkers (P-1333)

Keywords: Diagnostics

Getting to know you chances of dying can be daunting but also can be rather useful and fascinating. The kit predicts all-cause mortality independent of underlying diseases or the ?epigenetic clock?. It has been validated through a 14 year long patient study.

Lichter, Pfister, Witt, Jones, Sturm, Plass, Korshunov, Pfaff, Jabado

Histone mutations as marker for Glioblastoma (P-1012)

Keywords: Diagnostics

This technology was achieved by a cooperation between McGill University and DKFZ. Brain tumours, such as the highly aggressive glioblastoma multiforme (GBM), are currently the leading cause of cancer-related mortality and morbidity in children. Current diagnosis of brain cancers involve MRI, PET and CT scans, angiographies, followed by biopsies performed either during the resection of the tumor or as a separate procedure via a burr hole. A blood-based test would provide a more economical, i.e accessible and less invasive diagnostic tool. The GBM specific biomarker has been patented and is available for licensing i.e. for companion diagnostics. more...

von Deimling, Buckel, Balss, Pusch

Diagnosis of glioblastoma and acute myeloid leukaemia by (D)-2-hydroxyglutarate test (P-977)

Keywords: Diagnostics

Diagnosis and monitoring of IDH1/IDH2/IDH3 dependent diseases such as: Glioblastomas, astrocytoma, oligodendrogliomas, oligoastrocytoma, acute myeloid leukaemia (AML), chondrosarcoma, intrahepatic cholangiocarcinoma, angioimmunoblastic T cell lymphoma. The technolgy describes a patented test, which is a simple and robust enzymatic assay with a readout in 3 hours. The test is suitable for 96-/384-well format, less expensive/time-consuming and high-throughput possible in opposite to established GC-MS test. more...

Moldenhauer, Scheffzek, Parret

Monoclonal Antibody against Neurofibromin: Diagnostic and Prognostic Marker for Glioma Treatment (N terminal antibody: mAb NF1-5.16) (P-897)

Keywords: Diagnostics

Monoclonal Antibody against Neurofibromin as a diagnostic and prognostic Marker for Glioma Treatment. The proof of concept is established with Biopsy Material. The antibody is fast, reliable & ready to use.

to top
powered by webEdition CMS